<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34606">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656069</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-301</org_study_id>
    <nct_id>NCT02656069</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics</brief_title>
  <official_title>G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen™
      (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for
      hypoglycemia rescue of adult patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded, randomized, Phase 3 comparative efficacy and safety study in adults with
      type 1 diabetes. Patients will complete screening procedures up to 60 days before
      randomization to determine eligibility before enrollment to the treatment phase.

      The procedure for evaluating the efficacy of the G-Pen™ (glucagon injection) consists of
      inducing hypoglycemia by intravenous administration of regular insulin diluted in normal
      saline. Each participant will undergo two episodes of insulin-induced hypoglycemia, and in
      random order will receive 1 mg G-Pen™ (glucagon injection) during one episode and 1 mg Lilly
      Glucagon during the other episode. There will be wash out period of 7-28 days between
      treatment visits.

      Blood glucose levels will be monitored post-dosing, with a return of plasma glucose to a
      concentration &gt; 70 mg/dL within 30 minutes signifying successful hypoglycemia rescue. As a
      confirmation of efficacy, subjects will complete a questionnaire concerning changes in
      symptoms of hypoglycemia following treatment with glucagon.

      Subjects will return for a follow-up safety visit 3-14 days following administration of the
      final dose of glucagon.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemia rescue</measure>
    <time_frame>At 30 minutes following administration of study drug</time_frame>
    <description>Treatment success will be based on a primary endpoint of an increase in plasma glucose concentration from below 50 mg/dL to greater than 70 mg/dL within 30 minutes after administration of glucagon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose area under the curve (AUC)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose AUC from baseline to 4 hours following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose maximum concentration (Cmax)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose Cmax from baseline to 4 hours following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose time to maximum concentration (Tmax)</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of plasma glucose Tmax from baseline to 4 hours following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose time to concentration &gt; 70 mg/dL</measure>
    <time_frame>At -5, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes following administration of glucagon</time_frame>
    <description>Pharmacodynamic endpoint of time from baseline to achieve a plasma glucose concentration &gt; 70 mg/dL following administration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia symptoms</measure>
    <time_frame>At 0, 5, 10, 15, 20, 25 and 30 minutes following administration of glucagon</time_frame>
    <description>Change in autonomic and neuroglycopenic symptoms from baseline through 30 minutes following administration of glucagon.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen™ (glucagon injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen™ (glucagon injection)</intervention_name>
    <description>1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector</description>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly Glucagon (glucagon injection [rDNA origin])</intervention_name>
    <description>1 mg of Lilly glucagon reconstituted from lyophilized powder</description>
    <arm_group_label>G-Pen first, then Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon first, then G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with type 1 diabetes mellitus for at least 24 months

          -  usage of daily insulin treatment

          -  random serum C-peptide concentration &lt; 0.5 ng/mL

        Exclusion Criteria:

          -  pregnant or nursing

          -  HbA1c &gt;9.0%

          -  renal insufficiency

          -  hepatic synthetic insufficiency

          -  aspartate or alanine aminotransferase &gt; 3 times the upper limit of normal

          -  hematocrit less than or equal to 30%

          -  use of &gt; 2.0 U/kg total insulin dose per day

          -  inadequate bilateral venous access in both arms

          -  congestive heart failure, New York Heart Association class II, III or IV

          -  active malignancy within 5 years, except basal cell or squamous cell skin cancers

          -  history of breast cancer or malignant melanoma

          -  major surgical operation within 30 days

          -  current seizure disorder.

          -  current bleeding disorder, treatment with warfarin, or platelet count below 50,000

          -  history of pheochromocytoma or disorder with increased risk of pheochromocytoma

          -  history of insulinoma

          -  history of glycogen storage disease.

          -  positive for HIV, hepatitis C virus or active hepatitis B virus infection

          -  whole blood donation of 1 pint (500 mL) within 8 weeks

          -  active substance or alcohol abuse

          -  administration of glucagon within 28 days

          -  participation in other studies involving an investigational drug or device within 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Wilson, RN</last_name>
      <phone>205-934-4112</phone>
      <email>tlperkins@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Fernando Ovalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Guzman</last_name>
      <phone>619-427-1300</phone>
      <email>paula.guzman@prosciento.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Contreras</last_name>
      <phone>619-427-1300</phone>
      <email>laura.contreras@prosciento.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bedolla</last_name>
      <phone>760-466-1523</phone>
      <email>Lbedolla@amcrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Bailey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Galdes</last_name>
      <phone>925-930-7267</phone>
      <email>egaldes@diabloclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mark Christiansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Guerrero, BS</last_name>
      <phone>210-949-0122</phone>
      <email>aguerro@cttexas.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Denham, DO, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hughes</last_name>
      <phone>425-251-1720</phone>
      <email>rcrc@rainier-research.com</email>
    </contact>
    <investigator>
      <last_name>Leslie Klaff, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>January 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
